Equities Analysts Set Expectations for HeartBeam Q3 Earnings

HeartBeam, Inc. (NASDAQ:BEAT) – Research analysts at HC Wainwright upped their Q3 2026 earnings per share (EPS) estimates for shares of HeartBeam in a note issued to investors on Tuesday, September 22nd. HC Wainwright analyst Y. Chen now forecasts that the medical research company will post earnings per share of ($0.09) for the quarter, up from their prior forecast of ($0.10). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for HeartBeam’s current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for HeartBeam’s Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.37) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at ($0.06) EPS, Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.24) EPS.

HeartBeam (NASDAQ:BEAT) last announced its earnings results on Thursday, August 13th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01).

Other analysts have also recently issued reports about the stock. Maxim Group initiated coverage on shares of HeartBeam in a report on Tuesday, July 14th. They issued a “buy” rating and a $2.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of HeartBeam in a report on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $4.00.

HeartBeam Trading Down 10.3%

BEAT stock opened at $0.39 on Thursday. HeartBeam has a twelve month low of $0.39 and a twelve month high of $4.00. The company has a market capitalization of $21.91 million, a P/E ratio of -0.76 and a beta of -0.80. The firm has a 50 day simple moving average of $0.49 and a 200-day simple moving average of $0.78.

Institutional Investors Weigh In On HeartBeam

A number of institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in HeartBeam during the second quarter worth $741,000. Beacon Pointe Advisors LLC bought a new stake in HeartBeam during the second quarter valued at $185,000. Finally, Sigma Planning Corp raised its holdings in shares of HeartBeam by 86.9% during the second quarter. Sigma Planning Corp now owns 247,700 shares of the medical research company’s stock worth $186,000 after purchasing an additional 115,150 shares during the period. 7.77% of the stock is currently owned by institutional investors.

Trending Headlines about HeartBeam

Here are the key news stories impacting HeartBeam this week:

• Positive Sentiment: HC Wainwright raised multiple earnings estimates. The analyst increased its forecasts for Q3 and Q4 2026, all four quarters of 2027, FY2026, and FY2027. The FY2027 loss estimate improved to $(0.24) per share from $(0.31), while the FY2026 loss estimate improved to $(0.37) from $(0.41). These revisions suggest expectations for slower cash burn or improving operating performance. HeartBeam earnings estimates
• Neutral Sentiment: HeartBeam is reportedly shifting focus toward heart-attack detection technology. The strategic emphasis could improve the company’s commercial opportunity if the technology gains clinical or regulatory traction, but the available report provides no new approval, partnership, or revenue details. HeartBeam shifts focus to heart-attack detection technology
• Negative Sentiment: HC Wainwright downgraded BEAT from “Buy” to “Neutral.” The downgrade is a more immediate negative catalyst and signals reduced conviction in the stock’s risk-reward profile. It is especially significant because HeartBeam continues to report losses, with the latest quarterly EPS missing expectations and the consensus full-year forecast still calling for a $(0.41) loss per share. HeartBeam stock rating lowered by HC Wainwright

About HeartBeam

HeartBeam, Inc develops wearable and digital cardiac-monitoring technologies designed to help detect and evaluate heart conditions outside traditional clinical settings. The company’s platform is intended to capture electrocardiogram (ECG) data in a portable, cable-free format and transmit that information through a connected mobile device.

HeartBeam’s technology is based on three-dimensional vector ECG recordings, which are designed to provide electrical views of the heart from multiple directions rather than relying solely on a conventional single-lead wearable reading.